Expression of the breast and ovarian cancer susceptibility gene BRCA1 is down-regulated in sporadic breast and ovarian cancer cases. Therefore, the identification of genes involved in the regulation of BRCA1 expression might lead to new insights into the pathogenesis and treatment of these tumors. In the present study, an ''inverse genomics'' approach based on a randomized ribozyme gene library was applied to identify cellular genes regulating BRCA1 expression. A ribozyme gene library with randomized target recognition sequences was introduced into human ovarian cancer-derived cells stably expressing a selectable marker [enhanced green fluorescence protein (EGFP)] under the control of the BRCA1 promoter. Cells in which BRCA1 expression was upregulated by particular ribozymes were selected through their concomitant increase in EGFP expression. The cellular target gene of one ribozyme was identified to be the dominant negative transcriptional regulator Id4. Modulation of Id4 expression resulted in inversely regulated expression of BRCA1. In addition, increase in Id4 expression was associated with the ability of cells to exhibit anchorage-independent growth, demonstrating the biological relevance of this gene. Our data suggest that Id4 is a crucial gene regulating BRCA1 expression and might therefore be important for the BRCA1 regulatory pathway involved in the pathogenesis of sporadic breast and ovarian cancer.

We have investigated the covalent modification of the proteins encoded by the murine fos proto-oncogene (c-fos) and that of the corresponding gene product of FBJ murine osteosarcoma virus (v-fos). Both proteins are posttranslationally processed in the cell, resulting in forms with lower electrophoretic mobilities than that of the initial translation product on sodium dodecyl sulfate-polyacrylamide gels. Treatment with alkaline phosphatase indicates that most, if not all, of this electrophoretic shift is due to phosphoesterification of both proteins. These phosphoryl groups stoichiometrically modify the v-fos and c-fos proteins on serine residues and turn over rapidly in vivo in the presence of protein kinase inhibitors (half-life, < 15 min [32P]phosphate-labeled proteins indicates that although the two proteins have several tryptic phosphopeptides in common, the c-fos protein contains unique major tryptic phosphopeptides that the v-fos protein lacks. These unique sites of c-fos phosphorylation have been tentatively localized to the carboxy-terminal 20 amino acid residues of the protein. Phosphorylation of the c-fos protein, but not the v-fos protein, can be stimulated at least fivefold in vivo by the addition of either 12-tetradecanoyl-phorbol-13-acetate or serum. This increase in the steady-state degree of phosphorylation of c-fos appears to be independent of protein kinase C since phosphorylation is Ca2+ and diacylglycerol independent. The possible role of phosphorylation of these proteins in cellular transformation is discussed.

Recombinant adenoassociated virus (rAAV) type 2 vectors have been used to transduce a wide variety of cell types, including hematopoietic progenitor cells. For in vivo gene transfer, it is desirable to have an rAAV vector that specifically transduces selected target cells. As a first step toward generating an rAAV vector capable of targeting delivery in vivo, we have engineered a chimeric protein combining the AAV capsid protein and the variable region of a single-chain antibody against human CD34 molecules, a cell surface marker for hematopoietic stem/progenitor cells. Inclusion of the chimeric CD34 single-chain antibody-AAV capsid proteins within an rAAV virion significantly increased the preferential infectivity of rAAV for the CD34+ human myoleukemia cell line KG-1, which is normally refractory to rAAV transduction. Antibodies against the single-chain antibody and the CD34 protein blocked this transduction. This chimeric vector represents a significant improvement in the host range of rAAV and the first step toward specific gene delivery by rAAV vectors to cells of choice, in this case, hematopoietic progenitor cells, for the treatment of human disease.

Ribozymes are small catalytic RNA molecules that can be engineered to enzymatically cleave RNA transcripts in a sequence-specific fashion and thereby inhibit expression and function of the corresponding gene product. With their simple structures and site-specific cleavage activity, they have been exploited as potential therapeutic agents in a variety of human disorders, including hepatitis C virus (HCV) infection. We have designed a hairpin ribozyme ( Ribozymes are small catalytic RNA molecules that hybridize to complementary sequences of a particular target mRNA and that can be engineered to enzymatically cleave and destroy RNA transcripts in a sequence-specific fashion, thereby preventing expression and function of the corresponding gene product. Ribozymes have been studied in connection with a variety of diseases and human disorders as potential therapeutic molecules (for recent reviews see references 2, 9, 15, 19, and 22). Hairpin ribozymes fold into a two-dimensional hairpin structure, consisting of a small catalytic region with four helical domains (see Fig. 1A). Based on Watson-Crick base pairing, the ribozyme binding arms (helices 1 and 2) hybridize to sequences flanking the cleavage site (GUC) within the target RNA, thereby determining specificity of the recognized target sequence.Recently, we introduced a novel "inverse genomics" procedure based on a retrovirus hairpin ribozyme library with randomized target recognition sequences for gene discovery in different experimental systems. These include (i) genes regulating the BRCA1 promoter (3), (ii) cellular genes mediating hepatitis C virus (HCV) internal ribosome entry site (IRES) activity (14), (iii) genes involved in anchorage-independent cell growth control (23), and (iv) genes involved in suppression of fibroblast transformation (16). Ribozymes that repeatedly conferred distinct cellular phenotypes were selected in these systems. Single ribozyme candidates were identified, and the binding sequence flanking the GUC site required for ribozyme cleavage was exploited to identify partial sequence information of the target gene responsible for the observed phenotype. For the HCV IRES project, a cellular selection scheme was developed using a reporter system based on herpes simplex virus (HSV) thymidine kinase (TK) as a negative selectable marker under translational control of the HCV IRES (14). This cellular selection system allowed the identification of ribozymes that actively inhibited HCV IRES-mediated translation of HSV TK and thereby conferred a ganciclovir (GCV)-resistance phenotype. By using the ribozyme binding sequences, potential cellular cofactors for HCV IRES were discovered (14). For these experiments, Rz3ЈX, a hairpin ribozyme engineered against the minus-strand HCV replication intermediate at position 40 within the terminal 98-nucleotide (nt) (3ЈX tail)

Arimoclomol is an investigational drug for amyotrophic lateral sclerosis (ALS) that amplifies heat shock protein gene expression during cell stress. The objectives of the present study were to assess the safety, tolerability, and pharmacokinetics of arimoclomol in ALS. Eighty-four participants with ALS received arimoclomol at one of three oral doses (25, 50, or 100 mg three times daily) or placebo. The primary outcome measure was safety and tolerability. A subset of 44 participants provided serum and cerebrospinal fluid (CSF) samples for pharmacokinetic analysis. Participants who completed 12 weeks of treatment could enroll in a 6-month open-label study. Arimoclomol at doses up to 300 mg/day was well tolerated and safe. Arimoclomol resulted in dose-linear pharmacologic exposures and the half-life did not change with continued treatment. Arimoclomol CSF levels increased with dose. Arimoclomol was shown to be safe, and it crosses the blood-brain barrier. Serum pharmacokinetic profiles support dosing of three times per day. An efficacy study in ALS is planned.